ScholarIQanswers from OpenAlex & ORCID
Jaime Mejia
ResearcherPublications, citations & collaboration network
Jaime Mejia is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jaime Mejia have?
ScholarIQindexed works
Jaime Mejia has 104 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jaime Mejia have?
ScholarIQcitation count
Jaime Mejia has 5,907 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jaime Mejia?
ScholarIQh-index
Jaime Mejia has an h-index of 16 in OpenAlex.
What is the i10-index of Jaime Mejia?
ScholarIQi10-index
Jaime Mejia has an i10-index of 23 in OpenAlex.
What is the ORCID of Jaime Mejia?
ScholarIQorcid
The ORCID for Jaime Mejia is on the source record.
What is the OpenAlex record for Jaime Mejia?
ScholarIQopenalex
The OpenAlex for Jaime Mejia is on the source record.
What are the most-cited papers on Jaime Mejia?
ScholarIQmost cited works
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice André, Attila Tordai, Jaime Mejia, W. Fraser Symmans, Ana M. González-Angulo, Bryan T. Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobágyi, Lajos Pusztai
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
Kenneth R. Hess, K. Anderson, W. Fraser Symmans, Vicente Valero, Nuhad K. Ibrahim, Jaime Mejia, Daniel J. Booser, Richard L. Theriault, Aman U. Buzdar, Peter J. Dempsey, Roman Rouzier, Nour Sneige, Jeffrey S. Ross, Tatiana Vidaurre, Henry Gómez, Gabriel N. Hortobágyi, Lajos Pusztai
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortés
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice André, Attila Tordai, Jaime Mejia, W. Fraser Symmans, Ana M. González-Angulo, Bryan T. Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobágyi, Lajos Pusztai